Penile Traction Device Studies & Clinical Evidence: What the Published Research Actually Shows

That summary is deliberately framed around its central limitation: there is no large randomized sham-controlled trial of penile traction for general cosmetic length gain. What exists is a body of small prospective cohort studies, two randomized controlled trials in specific clinical populations, and one pooled meta-analysis — genuine, internally consistent evidence, but not a single gold-standard trial of general length gain. The sections below set out how the studies were built, what each cohort found, why dropout reframes the headline numbers, and where the evidence stops.

Reading a study honestly means understanding how it was built. The penile traction literature uses a small set of recurring designs, and the vocabulary below is what a reader needs to judge what the numbers can — and cannot — prove.

Prospective cohort / single-arm trial

A prospective cohort study enrols a group of men, records a baseline stretched or flaccid length, applies a calibrated daily-wear protocol, and re-measures at follow-up. Most penile traction studies take this single-arm form — there is usually no separate control group receiving a sham device.

Pooled meta-analysis

A pooled meta-analysis statistically combines results across multiple separate trials. Almsaoud 2023 (PMID: 36895692) pooled twelve heterogeneous traction-therapy trials to calculate a single weighted pooled mean length gain of approximately 1.9 cm (0.75 inches).

Completer analysis vs intention-to-treat

A completer analysis reports outcomes only for men who finished the protocol; an intention-to-treat analysis counts everyone who started, including dropouts. Most traction studies report completer figures, which makes the dropout rate a key number when interpreting results.

Daily-wear protocol

The daily-wear protocol is the prescribed regimen — typically 2–6 hours per day of calibrated traction over 2–6 months. Levine & Rybak 2011 used 2–4 hours per day across 2–4 months; Gontero 2009 used 4–6 hours per day across six months.

Baseline and follow-up measurement

Outcomes are recorded as the change from a baseline measurement — stretched, flaccid, or erect penile length — to a follow-up measurement at the end of the protocol. Which length is measured matters: flaccid and stretched length are measured far more often than erect length.

Understanding the design tells you what a number means. A "+1.5 cm" completer figure from a single-arm cohort is a real measurement, but it is not the same kind of evidence as a result from a large sham-controlled trial. These protocol durations also explain the results timeline covered in penis extender results: before and after, and the underlying tissue response is detailed in how a penile traction device works.

Six published studies anchor the penile traction evidence base. Ordered by strength of design — the pooled meta-analysis and the two randomized controlled trials before the single-arm cohorts — they use different cohorts, durations, and measurement endpoints, yet converge on the same modest range.

Almsaoud 2023 (PMID: 36895692) is the strongest single piece of evidence. This 2023 systematic review and meta-analysis of penile traction in men with Peyronie's disease combined twelve heterogeneous traction-therapy trials and calculated a 1.9 cm pooled mean length gain (Almsaoud 2023, PMID: 36895692) — approximately 0.75 inches. Across the broader calibrated-traction safety literature, mild adverse events are reported in roughly 11–14% of users, with no serious adverse events identified. Because it aggregates many trials, the meta-analysis confirmed that the modest length-gain signal is not an artefact of any one cohort.

Joseph 2020 (RestoreX) reported the open-label and follow-up phases of the RestoreX penile traction programme in 110 men with Peyronie's disease. Across that cohort, 94% achieved increased penile length, with a mean gain of approximately +1.6 cm (0.6 inches) — and gains up to 2.0–2.3 cm (0.8–0.9 inches) in consistent users — alongside adherence above 85% and minimal adverse events.

Toussi 2021, PMID: 34060339, is a single-centre randomized controlled trial of 82 men evaluating penile traction after radical prostatectomy. Over six months, the traction group demonstrated a mean penile length gain of +1.6 cm (0.6 inches) against +0.3 cm (0.1 inches) in the control group (p<0.01) — the closest the literature comes to a controlled length-gain comparison, though conducted in a post-prostatectomy rather than a general cosmetic population.

Levine & Rybak 2011, PMID: 21492409, pre-prosthesis short-penis cohort studied men with a shortened penis prior to penile prosthesis implantation. Calibrated traction worn 2–4 hours per day for 2–4 months reported approximately +1.5 cm (0.6 inches) of erect length gain in roughly 70% of subjects, with no adverse events reported. It is one of the few studies to measure erect length directly.

Gontero 2009, PMID: 19138361 was a phase II prospective cohort of fifteen men that applied calibrated medical traction at 4–6 hours per day for six months. The study observed a mean flaccid length gain of approximately +1.3 cm (0.5 inches).

Nikoobakht 2011, PMID: 20102448 was a prospective cohort of twenty-three men with a shortened penis. Calibrated traction applied over three months demonstrated a mean flaccid length gain of approximately +1.7 cm (0.7 inches).

The credibility of this evidence lies in its convergence. Six studies, six different cohorts and protocols, two different length endpoints — yet all land inside a modest 1.3–1.9 cm (0.5–0.75 inches) band. That agreement across independent designs — including the controlled comparison in Toussi 2021 — is what makes the body of evidence trustworthy, even though no large sham-controlled trial of general cosmetic length gain exists. The same evidence is applied to a specific cohort in penile traction device for small penis, and the practical "does it work" reading is covered in do penis extenders really work.

One number quietly shapes every traction result: how many men finished the study. Penile traction asks for hours of daily wear over months, and in every cohort some men stop early. Understanding that dropout is essential to reading the headline figures honestly.

• What dropout means. The protocol demands sustained daily wear over 2–6 months. The men who stop before it ends are non-completers; those who finish are completers.
• Why completer rates inflate apparent results. Reported gains usually describe completers only. A study reporting "+1.3 cm" is describing the men who wore the device consistently — not the average across everyone who enrolled.
• Compliance is the strongest predictor. Across the literature, consistent daily wear is the single factor most associated with measurable gain. The roughly 70% responder figure in Levine & Rybak 2011 reflects a compliant pre-prosthesis cohort.
• The honest reading. The pooled mean of roughly 1.9 cm (0.75 inches) from Almsaoud 2023 is a realistic expectation for a man who completes the protocol — not a guarantee for a man who wears the device sporadically.

So when you read any traction study, ask how many men finished. The answer reframes the headline number — and it is also why the results timeline in penis extender results: before and after is framed around months of consistent wear rather than a quick outcome.

A transparent evidence page states its own limits. The penile traction literature supports modest, real length gain in compliant users — and five honest limitations bound exactly how far that conclusion can be pushed.

1. No large sham-controlled trial for general length gain. Randomized controlled evidence does exist — Toussi 2021 in a post-prostatectomy cohort, and the RestoreX programme reported by Joseph 2020 in Peyronie's disease — but there is no large randomized sham-controlled trial of traction for general cosmetic length gain, the design that would most firmly establish cause and effect in that population. Most general length-gain evidence remains small single-arm prospective cohorts.
2. Small sample sizes. Individual cohorts enrolled modest numbers of men — Gontero 2009 fifteen, Nikoobakht 2011 twenty-three — which limits statistical precision and the confidence of any single result.
3. Heterogeneity. Almsaoud 2023 pooled trials that used different devices, durations, cohorts, and measurement endpoints. That heterogeneity is a documented limitation of the pooled estimate, even though it also shows the signal is not device-specific.
4. No support for dramatic gains. Nothing in the published literature supports "+2 inches" or "+3 inches" marketing claims. The evidence supports a modest pooled mean of roughly 1.9 cm (0.75 inches), and a man should read it as exactly that.
5. Scope limited to calibrated medical-grade devices. The studied outcomes were produced by calibrated FDA-registered medical traction devices — not uncalibrated marketplace clamps. A device outside that category is not part of this evidence base; see medical-grade penile traction device for what that scope limit means.

Stating these limits is not a weakness of the evidence — it is what makes the rest of it credible. The research supports modest, real gain in compliant users of calibrated devices, and it does not support more than that. Curvature-focused traction for Peyronie's disease is a separate cohort with its own evidence base, set out in penile traction device for Peyronie's disease.

SizeGenetics is an FDA-registered Class II medical device — a calibrated medical traction device of exactly the category evaluated by the meta-analytic literature, including Almsaoud 2023 (PMID: 36895692). FDA registration is a manufacturer-and-device listing process and is not the same as FDA approval; what that classification involves is set out on the FDA-registered Class II medical device page.

The honest framing matters here. No single published study is "the SizeGenetics study" — this page does not present the device as the subject of a proprietary trial. Instead, the published evidence base applies to calibrated medical traction devices as a class, and SizeGenetics belongs to that class as an FDA-registered Class II medical device. It is manufactured in Lyngby, Denmark since 1995 and was co-invented by Dr. Jørn Ege Siana, board-certified plastic surgeon. A reader weighing the device against the evidence can review the full product detail on the SizeGenetics medical traction device page and the device qualities that the evidence rewards in the best penile traction device guide.

Co-Inventor of SizeGenetics

Dr. Jørn Ege Siana, M.D.

SizeGenetics was co-invented by Dr. Jørn Ege Siana, board-certified plastic surgeon. His clinical background shaped the device as a regulated medical instrument designed to deliver calibrated, sustained traction of the kind evaluated across the published evidence base.

• Board-certified plastic surgeon
• Co-inventor of the SizeGenetics penile traction device
• Medical advisor (legacy), Copenhagen

The evidence hub connects to the wider device-education cluster — starting with penile traction device: how medical devices deliver therapy. Each page below answers the logical next question for a reader weighing the research.